Enanta Pharmaceuticals
ENTA
127 hedge funds and large institutions have $312M invested in Enanta Pharmaceuticals in 2026 Q3 according to their latest regulatory filings, with 22 funds opening new positions, 38 increasing their positions, 43 reducing their positions, and 13 closing their positions.
98% more capital inflows, than outflows
Capital inflows: $78M | Capital outflows: $39.4M
79% more call options, than puts
Call options by funds: $402K | Put options by funds: $225K
69% more first-time investments, than exits
New positions opened: 22 | Existing positions closed: 13
4% more funds holding
Funds holding: 122 → 127 (+5)
12% less repeat investments, than reductions
Existing positions increased: 38 | Existing positions reduced: 43
12.52% less ownership
Funds ownership: 93.73% → 81.21% (-13%)
100% less funds holding in top 10
Funds holding in top 10: 1 → 0 (-1)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
BlackRock
New York
|
+$8.48M |
| 2 |
ADAR1 Capital Management
Austin,
Texas
|
+$5.16M |
| 3 |
Longaeva Partners
Chicago,
Illinois
|
+$3.01M |
| 4 |
Millennium Management
New York
|
+$1.74M |
| 5 |
Citadel Advisors
Miami,
Florida
|
+$1.17M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Farallon Capital Management
San Francisco,
California
|
-$19.5M |
| 2 |
Deep Track Capital
Greenwich,
Connecticut
|
-$5.9M |
| 3 |
Geode Capital Management
Boston,
Massachusetts
|
-$1.89M |
| 4 |
Renaissance Technologies
New York
|
-$1.12M |
| 5 |
Mackenzie Financial
Toronto Ontario,
Ontario, Canada
|
-$982K |
ENTA Hedge Fund Activity: Q3 2026 in Review
127 of the 8,114 institutional investors tracked by Wall St. Rank reported a position in Enanta Pharmaceuticals (ENTA) for Q3 2026, worth a combined $312M — down 22% from $397M a quarter earlier.
Buyers outnumbered sellers: 22 funds opened new ENTA positions and 13 closed out — a net gain of 9 holders — while 38 added to existing stakes and 43 trimmed.
The largest buyer was BlackRock, adding an estimated $8.48M. The largest seller was Farallon Capital Management, cutting an estimated $19.5M.
- 127 institutional investors held Enanta Pharmaceuticals (ENTA) as of Q3 2026, up from 122 in Q2 2026.
- Funds reported $312M of Enanta Pharmaceuticals stock for Q3 2026, down 22% quarter-over-quarter.
- 22 funds opened new Enanta Pharmaceuticals positions in Q3 2026 and 13 closed out, a net change of +9 holders.
- The largest Enanta Pharmaceuticals buyer in Q3 2026 was BlackRock, an estimated $8.48M added.
- The largest Enanta Pharmaceuticals seller in Q3 2026 was Farallon Capital Management, an estimated $19.5M sold.
Based on aggregated 13F filings for Q3 2026.